Camptothecin (CPT), a topoisomerase I-specific inhibitor, was found in this study to inhibit the replication of equine infectious anemia virus (EIAV) in chronically infected CF2Th cells (designated CF2Th/EIAV). By measuring viral reverse transcriptase activity in the culture medium, we demonstrated that treatment for 1 h with noncytotoxic doses of this drug inhibited production by 32 to 52%, whereas continuous exposure to this drug resulted in an 85 to 92% inhibition. No effect on the viability or growth rate of the cells was detected in any of these treatments. Indirect immunofluorescence analysis of the CPT-treated CF2Th/EIAV cells with anti-p26 capsid protein antibodies showed 60 to 85% reduction in the immunofluorescence-positive cells following drug treatment, and radioimmunoprecipitation analysis of these cells showed a comparable decrease of the pr559ag precursor protein. These data suggest that CPT acts as an anti-EIAV agent to block virus replication in the chronically infected cells.
Equine infectious anemia virus (EIAV) is a member of the Lentivirinae subfamily of retroviruses (2, 8) . This group also includes the causative agent of AIDS, the human immunodeficiency virus (HIV) (3, 8) . Injection of horses with EIAV results in persistent infection accompanied by viremia, fever, anemia, tissue injury, and erythrocyte destruction (14, 16) . The virus infects cells of the monocyte or macrophage lineage, and stress or immunosuppression may precipitate a resumption of clinical disease (13, 15) . Recent studies revealed morphological and structural similarities between EIAV and HIV (23, 25) .
We have recently shown that topoisomerase I (TOPO-I) activity is present in EIAV, HIV type 1 (HIV-1), and Moloney murine leukemia virus particles. In the case of EIAV, the enzyme was located in the viral cores. Furthermore, this virus-associated enzyme differs in its characteristics from the cellular TOPO-I. We have also demonstrated that the EIAV pll nucleocapsid protein and the cellular TOPO-I share similar epitopes (21) . We have found that virus-associated TOPO-I activity is inhibited by camptothecine (CPT), a known specific inhibitor of eukaryotic TOPO-I (1, 12, 24) . CPT is a natural product derived from the Asian tree, Camptotheca acuminata (26) , which has strong antitumor activity against a wide range of experimental tumors (4, 26) and human colon cancer (5) . In its cytotoxic doses, CPT inhibits RNA and DNA synthesis and causes rapid and reversible fragmentation of DNA in mammalian cells (11, 24, 26) . It has been shown that DNA TOPO-I is the main, if not the exclusive, target of CPT (1) . In addition, we have demonstrated that noncytotoxic doses of CPT inhibit HIV-1 replication in acute infection of H9 cells (20) . In this work, we extended our studies and demonstrated an inhibition of (106 per flask) were treated with different doses of CPT for 1 h at 37°C, washed, and resuspended in fresh medium. Reverse transcriptase (RT) activity in the culture medium was measured 48 h (or as otherwise indicated) posttreatment as described previously (6 RIPA. CF2Th/EIAV cells were or were not exposed to 0.02 ,uM CPT and radioactively labelled for 16 h at 37°C with 35S-methionine (500 ,uCi per flask) (Amersham). Labelled cells were washed twice in serum-free Dulbecco modified Eagle medium. Sample cultures were taken for further analysis at the end of the labelling period, and the others were chased by addition of fresh medium for 48 and 72 h at 37°C (chase experiments). In addition, the culture medium from each time point was collected for virus purification. In order to precipitate viral proteins from the cells, 300 ,ul of radioimmunoprecipitation assay (RIPA) buffer (50 mM TrisCl, pH 7.5, 0.5 M NaCl, 0.5% Nonidet P-40, 0.25% Na deoxycholate, 0.1% sodium dodecyl sulfate [SDS]) was added to the labelled cells and cells were disrupted at 4°C by repeated aspiration through a 22-gauge needle. The supernatant was clarified by centrifugation for 1 h at 4°C (100,000 x g, 50 Ti rotor). The supernatant (107 cpm) was treated overnight at 4°C with EIAV p26 antiserum (9) (1:100 dilution) or with rabbit normal serum and then incubated for 2 h at 4°C with protein A-Sepharose (0.1 g/ml of RIPA buffer). The immunocomplexes were precipitated, washed five times with RIPA buffer, and analyzed on a 10% polyacrylamide gel. EIAV was purified from the culture medium by centrifugation through a Ficoll gradient (22) , and the pellet containing the virus was analyzed by immunoprecipitation with EIAV p26 antiserum as described above.
RESULTS
To investigate the effect of CPT on EIAV replication, it was first necessary to determine the appropriate dose of this drug that would inhibit replication without affecting the viability and growth rate of the host cell. For this purpose, 106 CF2Th/EIAV cells were treated with different CPT doses for 1 h at 37°C and washed and fresh medium was added. RT activity in the culture medium was measured 48 h after treatment, and cell viability and growth were determined 24 h, 48 h, and 7 days posttreatment. As shown in Fig. 1A (Fig. 2) . The reduction in IF-positive cells was 45% at 0.01 ,uM CPT, 60% at 0.02 ,uM CPT, and 85% at 0.1 ,uM CPT. To substantiate the IF results, we also measured the effect of CPT on viral protein expression by the immunoprecipitation assay. As shown in Fig. 3A , lane 2, CPT specifically inhibits the expression of the p26 precursor (i.e., pr559ag), while no effect on the total protein synthesis in the cells was Moreover, the chase experiments indicated a decrease in the labelled precursor in the untreated cells at 48 h postlabelling (Fig. 3A, lane 3) , whereas no such decrease was detected during this time in the CPT-treated cells (Fig. 3A,  lane 4) . At 72 h posttreatment, the labelled pr55 level decreased to a very low level in both CPT-treated and untreated cells; thus, we could not detect differences between the treated and untreated cells. In parallel, we also found labelled p26 capsid protein released into the culture medium of the untreated cells but not the culture medium of the CPT-treated cells at 24, 48 , and 72 h postlabelling (Fig.  3B) . The results are compatible with our previous RT data, further substantiating the antiviral inhibitory effect of CPT. 
DISCUSSION
The Lentivirinae group includes causative agents of severe diseases in humans and animals, such as HIV, EIAV, and simian immunodeficiency virus. A wide variety of antiviral drugs such as azidothymidine (18) and dideoxycytidine (17) are useful as antiviral drugs because of a more efficient inhibition of viral functions than cellular ones. The presence of TOPO-I activity in retroviral particles suggests a new target for developing potential antiviral drugs. In this paper, we show that treatment with the only known TOPO-Ispecific inhibitor, CPT, inhibits the replication of EIAV in chronically infected CF2ThIEIAV cells (32 to 52%) at doses which did not have any effect on cell viability. In contrast, amsacrine, which is a TOPO-TI-specific inhibitor, did not have any effect on EIAV replication at noncytotoxic or cytotoxic doses. The inhibition observed with noncytotoxic doses of CPT is consistent with a specific antiviral effect rather than a result of cell toxicity, since we have shown that continuous treatment with CPT results in a 92%o reduction in EIAV production in the absence of effects on cell viability. This inhibitory effect is most likely the result of reduced RNA expression, since we observed significant reductions in the levels of EIAV p26 and its precursor pr55gag proteins.
The number of p26-positive cells, as measured by IF, was reduced 85% following CPT treatment, and a significant reduction in the intracellular level of pr55gag precursor was detected by the RIPA. Moreover, we could not detect the release of EIAV p26 protein in the culture media from CPT-treated CF2Th/EIAV cells. These data are compatible Agents such as RT inhibitors (7, 18) , which block retroviral replication, act at early stages of the viral infection process, while other agents, such as alpha interferon, have been reported to suppress HIV expression in chronically infected cells (10) . CPT appears to act as an antiviral drug at both levels and is capable under certain conditions of both blocking the initial stage of retroviral infection and reducing viral production in chronically infected cells. It thus offers potential advantages over drugs that function only on one level.
TOPO-I is the main, if not the exclusive, target of CPT (1); thus, our results suggest that the inhibitory effect of CPT on EIAV replication is likely to be due to TOPO-I inhibition. Moreover, since low doses of CPT could inhibit the expression of EIAV p26 without affecting the total protein synthesis, viral RNA synthesis may be more highly sensitive to TOPO-I inhibition than most cell genes or TOPO-I may play a more direct role in the viral protein expression. We have shown a CPT-sensitive TOPO-I activity in EIAV cores (21) , and experiments are in progress in order to determine the role of TOPO-I in the EIAV life cycle.
